Antidiabetic drugs effective against Parkinson's disease and Dementia

A new study suggests that diabetes drugs known as SGLT2 inhibitors may lower the risk of dementia and Parkinson's disease. 

Published in Neurology, the study examined over 350,000 people with type 2 diabetes. 

It found that those taking SGLT2 inhibitors had a 20% reduced risk of Alzheimer's and Parkinson's disease, and a 30% reduced risk of vascular dementia, compared to those on other diabetes drugs.

 
While the findings are promising, more long-term research is needed to confirm these protective effects.